Avidity Biosciences, Inc. - Common Stock (RNA)

Novartis Q3 sales rose 8% to $13.91 billion, missing estimates, as Kisqali and Kesimpta drove growth while U.S. generics weighed on results.

U.S. companies have struck more than $80 billion worth of deals in the past 24 hours, in the latest sign that mergers and acquisitions (M&A) are picking up after the tariff-induced cool-off earlier this year.

If all goes well, the company will be part of a much larger enterprise starting next year.

Investor optimism drives the S&P 500 to new records while Qualcomm steals the spotlight with an 11% surge after unveiling new AI chips.

Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Avidity Biosciences (RNA) to be acquired by Novartis in a $12 billion cash deal. H.C. Wainwright downgrades to Neutral.

Qualcomm shares were up more than 11% in Monday’s midday session after the company unveiled two AI accelerator chips.

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.

The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash.

Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share.

U.S. stock futures rose on Monday following Friday’s positive moves. Futures of major benchmark indices were higher.